



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 6/00, 9/51, 9/22 A61K 9/20	A1	(11) International Publication Number: WO 92/00718 (43) International Publication Date: 23 January 1992 (23.01.92)
---	----	--

(21) International Application Number: PCT/US90/03762

(22) International Filing Date: 3 July 1990 (03.07.90)

(71) Applicant: ATRIX LABORATORIES, INC. [US/US];
1625 Sharp Point Drive, Fort Collins, CO 80525 (US).(72) Inventors: DUNN, Richard, L. ; 451 Boardwalk Drive,
Fort Collins, CO 80525 (US). TIPTON, Arthur, J. ; 412
Garfield, Fort Collins, CO 80524 (US). HARKRADER,
Ronald, J. ; 336 Van Buren Court, Louisville, CO 80027
(US). ROGERS, Jack, A. ; 713 Greenfield Court, Fort
Collins, CO 80524 (US).(74) Agent: HAMRE, Curtis, B.; Merchant, Gould, Smith,
Edell, Welter & Schmidt, 3100 Norwest Center, 90 South
Seventh Street, Minneapolis, MN 55402 (US).(81) Designated States: AT, AT (European patent), AU, BB, BE
(European patent), BF (OAPI patent), BG, BJ (OAPI
patent), BR, CA, CF (OAPI patent), CG (OAPI patent),
CH, CH (European patent), CM (OAPI patent), DE*,
DE (European patent)*, DK, DK (European patent),
ES, ES (European patent), FI, FR (European patent),
GA (OAPI patent), GB, GB (European patent), HU, IT
(European patent), JP, KP, KR, LK, LU, LU (European
patent), MC, MG, ML (OAPI patent), MR (OAPI pa-
tent), MW, NL, NL (European patent), NO, RO, SD,
+ SE, SE (European patent), SN (OAPI patent), SU, TD
(OAPI patent), TG (OAPI patent).

Published

With international search report.

(54) Title: INTRAGINGIVAL DELIVERY SYSTEMS FOR TREATMENT OF PERIODONTAL DISEASE

(57) Abstract

A polymeric controlled delivery system is provided for use in treating periodontal disease. The delivery system in a variety of forms is placed directly in the infected gingival tissue where the chemotherapeutic agent is slowly released into the tissue and into the infected periodontal pocket by means of the gingival crevicular fluid originating in the gingival tissue.

* DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

+ DESIGNATIONS OF "SU"

It is under examination in which parts of the former Soviet Union the designation of the Soviet Union has effect.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

INTRAGINGIVAL DELIVERY SYSTEMS FOR
TREATMENT OF PERIODONTAL DISEASE

5

Background of the Invention

Periodontal disease or gum disease as it is often called can be defined as an infection and inflammation of the gingiva or gums and loss of underlying alveolar bone support. There are varying levels of severity of the disease. The mildest cases are clinically termed gingivitis (inflamed and bleeding gums). More severe cases are clinically known as periodontitis and can involve loss of bone support. Gingivitis is reversible and can often be eliminated with a thorough dental prophylaxis followed by improved personal oral hygiene procedures. If gingivitis is not controlled, the disease often progresses into periodontitis.

Periodontitis is not only characterized by bacterial infection and inflammation, it is also accompanied by the formation of periodontal pockets (spaces between the teeth and gums) and bone deterioration which can lead to tooth loss. Periodontitis is recurring, progressive, and episodic. There is no cure at this time. Effective treatment is to apply professional intervention to halt disease progression.

Professional intervention may involve surgical or nonsurgical procedures. Nonsurgical treatment consists of periodic professional scaling, root planing, and soft tissue curettage, in combination with conscientious home care by brushing and flossing on the part of the patient. Surgical treatment involves gingivectomy and flap surgery to recontour the soft and hard tissue around the diseased areas.

In recent years, it has become increasingly recognized that control of periodontitis may be possible with the use of antimicrobial agents delivered to the infected site. Systemic antibiotics taken orally or intramuscularly have been successfully used, but due to

the concern about allergic responses, the development of resistance, and the treatment of the whole person rather than the specific infection site, their use is recommended only in the severest of periodontal cases.

5 Treatment by mouth rinse and other topically applied oral medicinal agents to penetrate into the periodontal pocket where they are needed. Irrigation of the pockets with these agents has shown some effects on gingivitis, but the short time of exposure with
10 irrigation solutions and the rapid removal of any therapeutic agent by the outward flow of the crevicular fluid make this type of treatment ineffective with severe cases of periodontitis.

 The most recent proposed methods of treating
15 periodontitis with the local delivery of chemotherapeutic agents have involved the placement of these agents directly into the periodontal pocket. These include the cellulose hollow fibers loaded with tetracycline described in U.S. Patent No. 4,175,326 to
20 Goodson, the ethylcellulose films loaded with metronidazole described in U.S. Patent No. 4,568,535 to Loesche, the absorbable putty-like material described in U.S. Patent No. 4,568,536 to Kronenthal, the ethylene vinyl acetate fibers loaded with tetracycline described
25 in the European patent application No. 84401985.1 to Goodson, and the biodegradable microspheres and matrix described in U.S. Patent No. 4,685,883 to Jernberg. All of these delivery systems involve placing the product directly into the periodontal pocket.

30 Although the space between the gingival tissue and the tooth in periodontal disease is called a pocket, it is really only a potential space in which bacteria can grow. The insertion of a delivery system within this potential space is more difficult than the simple
35 placement of a material within a well-defined pocket. Moreover, the shape of the pocket or potential space is not regular, but often contoured based upon the shape of

the tooth and the extent of the disease. Thus, placement of a film or fiber within the pocket requires careful fitting to fill the pocket but not extend beyond the gingival margin. Any material extending outside the pocket will be removed by normal oral hygiene procedures unless the material is either adhered to the tissue or tooth or covered by a periodontal dressing.

In addition to the retention problems associated with normal dental care, the outward flow of crevicular fluid and the mechanical action of the teeth and the gums during eating may cause most materials placed within the periodontal pocket to be expelled in a relatively short time. It is well known that carbon particles placed within a periodontal pocket are all displaced within a few hours. Because of these retention problems, most periodontal delivery systems for chemotherapeutic agents are either adhesively bound to the tooth or the tissue within the pocket. However, adhesion to a wet surface such as that within the pocket is extremely difficult and normally the adhesion deteriorates rapidly. Thus, retention within the pocket is short-lived.

The other solution to retention of a delivery system within the pocket is to use a periodontal dressing to cover the pocket. Periodontal dressings are also adhesives and their adhesions to wet surfaces such as a tooth or gum tissue is difficult; and most periodontal dressings do not adhere long within the mouth. In addition, they are uncomfortable to the wearer and they tend to collect food particles and bacteria.

Because of these problems with proper placement of a local delivery system within the periodontal pocket and the retention of the system for sufficient time to kill all of the periodontal pathogens, there is a need for a better delivery system to deliver chemotherapeutic agents to the site of infection. Moreover, recent

research indicates that the bacteria often responsible for periodontal disease exist not only in the periodontal pocket but also within the gingival tissue. This is especially true for localized juvenile periodontitis. The only way to treat this form of periodontal disease has been to administer systemic antibiotics which can attack the bacterial infection within the gingival tissue itself. Several researchers have recently shown that the bacteria responsible for periodontal disease have also been found in the tissue of patients with normal adult periodontitis.

Thus, delivery systems containing chemotherapeutic agents when placed within the periodontal pocket will kill the bacteria there, but these agents will not penetrate the gingival tissue to destroy the bacteria located intragingivally. These bacteria subsequently repopulate the periodontal pocket after the chemotherapeutic agent has been totally released or exhausted. There is therefore a need for a local delivery system that will destroy not only the periodontal pathogens within the periodontal pocket but also within the gingival tissues.

SUMMARY OF THE PRESENT INVENTION

The present invention relates to the use of controlled release systems for the delivery of chemotherapeutic agents to localized sites in the mouth for the treatment of periodontal disease. The method of treatment involves the placement of a polymeric delivery system directly into the gingival tissue that is infected rather than into the periodontal pocket that is formed between the infected tissue and the tooth.

The polymeric delivery system may consist of microspheres, microcapsules, liposomes, fibers, rods, films, or spheres. They may be fabricated from either biodegradable or nonbiodegradable polymers, although delivery systems fabricated from biodegradable polymers

are preferred because they do not require removal after the chemotherapeutic agent has been released. Also preferred are the delivery systems in the form of microspheres, microcapsules, nano-particles, and liposomes which can be injected directly into the gingival tissue. Liquid polymeric systems that can be injected into the gingival tissue to form solid implants are also preferred delivery systems.

When injected into the gingival tissue, the polymeric delivery systems release the bioactive agent directly into the infected tissue. The bioactive agent is released by diffusion or dissolution from the polymer or if the polymer is bioerodible the agent can be released as the polymeric device erodes or biodegrades. The release of the agent creates a high concentration of active material within the gingival tissue. If the agent released is antimicrobial, the local concentration is sufficient to destroy the bacteria causing the infection. If the agent is an anti-inflammatory drug, the concentration is sufficient to reduce the inflammation within the tissue. Because the gingival crevicular fluid in the periodontal pocket is formed from serum from within the gingival tissue, the active agent is transported to the periodontal pocket as the serum flows out of the tissue. If the active agent is an antimicrobial, the intragingival delivery system can achieve concentrations of drug sufficient to kill the bacteria both within the tissue as well as in the periodontal pocket.

This system provides a significant advantage over delivery systems placed within the periodontal pocket where the outward flow of crevicular fluid tends to remove the active agent from the pocket as it is released. This loss of active agent has been alleviated to some extent by the placement of periodontal dressings over the opening of the pocket or the use of adhesives or sutures to close the pocket. Because of the outward

flow of the crevicular fluid and the poor penetration of most active agents into tissue, the drugs released into the periodontal pocket from a delivery system placed within the pocket or outside the pocket are unable to achieve an effective concentration of drug within the infected gingival tissue.

In addition to achieving effective concentrations of the active agent within the gingival tissue and the periodontal pocket, the intragingival delivery system described in the present invention provides a reliable method for retention of the delivery system at the site of infection. The delivery system is retained by the gingival tissue until it is surgically removed or the polymer has degraded. Being located within the tissue, the intragingival delivery system (unlike a periodontal pocket delivery system) is not subject to untimely removal by the gingival crevicular fluid or the normal dental hygiene procedures such as brushing, flossing, or rinsing. Also, the location of the delivery system within the gingival tissue does not interfere with the reattachment of tissue to the tooth once the bacteria have been destroyed or the inflammation has been eliminated. A periodontal pocket delivery system prevents tissue reattachment unless it is removed or unless the delivery system degrades in a short time. An added advantage of the intragingival delivery system of this invention is that its retention and non-interference properties allow the active agent to be delivered for much longer times than those possible with a periodontal-pocket-delivery system. Thus, instead of the normal 5-14 days of delivery with a periodontal-pocket-delivery system, times of 1-6 months for delivery of bioactive agent can be achieved. This extended delivery time can be used to prevent reinfection of the site.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for treating periodontal disease by the use of an intragingival polymeric controlled delivery system. The polymeric delivery system in the form of microspheres, microcapsules, nanoparticles, or liposomes are injected directly into the infected gingival tissue where they release an active agent such as an antimicrobial or antibiotic to destroy bacteria or an anti-inflammatory agent to eliminate inflammation. The preferred delivery system consists of a biodegradable polymer such that the delivery system does not require removal once the drug has been depleted. The polymeric delivery system can also be in the form of a fiber, film, or rod which is surgically placed within the gingival tissue, but the preferred systems are those which can be injected into the tissue. A liquid polymeric system that forms a solid implant that forms a solid implant after injection into the tissue is preferred.

Although nonbiodegradable polymers can be used in this application, the biodegradable polymers are preferred because they do not require removal after drug depletion. Examples of biodegradable polymers which can be used in this application are polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), polyvinylpyrrolidone, polyethylene glycol, hydroxycellulose, methylcellulose, chitin, chitosan, gelatin, collagen, and copolymers, terpolymers, or combinations or mixtures of the above materials. It is understood by those skilled in the art that the degradation times of the polymers can be adjusted by

their composition, their molecular weights, catalysts, and the surface areas of the polymers.

The term drug or bioactive agent as used herein includes, without limitation, physiologically or pharmacologically active substances that act locally or systemically in the body. Representative drugs and biologically active agents to be used in this application include antimicrobials, antibiotics, anti-inflammatory agents, anti-infectives, peptide drugs, protein drugs, bone and tissue growth factors, analgesics, antigens, biological response modifiers, vaccines, and the benzophenanthridine alkaloids. To those skilled in the art, other drugs or bioactive agents that can be released in an aqueous environment can be utilized in the described intragingival delivery system. Also, various forms of the drugs or bioactive agents may be used. These include, without limitation, forms such as uncharged molecules, molecular complexes, salts, ethers, esters, amides, etc., which are biologically activated when injected into the body.

The amount of drug or bioactive agent incorporated into the intragingival delivery system depends upon the desired release profile, the concentration of drug required for a biological effect, and the length of time that the drug has to be released for treatment. There is no critical upper limit on the amount of drug incorporated into the delivery system except for the local tissue irritation or the toxicity of the drug. The lower limit of drug incorporated into the delivery system is dependent simply upon the activity of the drug and the length of time needed for treatment.

With certain drugs and polymers, the drug will be released by diffusion from the polymer matrix. The rate of release will be described by Fick's Law of Diffusion for polymeric systems. If the matrix is a monolithic device, the release rate will be first-order

in which there is a burst of drug initially followed by a gradually declining rate. If a reservoir device is used, the release rate will be zero-order in which there is a constant rate of release until the drug has been depleted. For other drugs and polymer, the drug will be released by simple dissolution in which the loading of drug and the porosity of the polymeric delivery system will control the rate of delivery. For other drugs, the release will depend upon the degradation rate of the polymer. The molecular weight of these drugs are so high that they will not diffuse through the matrix polymer and the only way for them to be released is for the polymer to erode or fragment due to biodegradation.

The drug and the polymer can be blended together using a variety of methods. The intimacy of mixing, particle size, and particle shape can be varied according to the intended use. High homogeneity can be obtained by mixing the components in the molten state, cooling and grinding the resulting solid. The same type of homogeneity can be achieved if both components are dissolved in a common solvent, the solvent removed to give a film, and the film ground into a powder. These particles can be sieved to obtain the desired particle size for injection and for drug release. These particles as prepared constitute a monolithic delivery system in which the drug is distributed within the polymer matrix. As such the rate of release will be first order.

However, the particles can be converted to reservoir systems by coating them with a layer of polymer which serves as a rate-controlling membrane. The particles can be coated by several methods including spray drying, fluid-bed coating, or microencapsulation. Although microencapsulation can be used to coat drug/polymer particles already formed, it can also be used directly to form microspheres or microcapsules containing drug using a variety of methods known to

those skilled in the art. These include solvent evaporation, phase separation, interfacial polymerization, hot melt, and spray drying. The type of polymer used for the coating, the uniformity of the coating, the thickness of the coating, and the size of the microspheres or microcapsules can be used to control the release of drug.

Other small particles which can be used for injection include liposomes. These drug delivery forms are formed by encapsulating various drugs in lipid bylayers. The liposomes formed are extremely small and can be injected easily into the body or the blood stream. The other particles or microcapsules are injected as fluid suspensions from syringes into subcutaneous or muscular tissue. Water or aqueous solutions of sodium chloride or sodium carboxymethyl cellulose can be used for these injections. Oils such as sesame or peanut may also be used for injection. If the polymer is soluble in a biocompatible solvent that once injected into the body disperses and leaves the polymer to form a solid, then the drug also dissolved or dispersed in the polymer solution may be injected directly into the body to form a solid implant. Also, if the polymer is injected into the body as a liquid prepolymer and then polymerizes further or crosslinks to form a solid, then the drug dispersed in the liquid prepolymer can be injected to form a solid implant.

For the other implants which are solids as formed, then a surgical incision or the use of a trochar is needed for implantation. These solid implants may be in the form of fibers, films, rods, cylinders, and pellets. The fibers can be formed by melt extrusion if the drug is stable at the melt-spinning temperature or by solution spinning where polymer is soluble in a solvent that is compatible with the drug. Rods and cylinders can be formed by the same method or they can be formed by injection molding or compression molding.

Pellets can also be formed by compression molding or injection molding.

DETAILED DESCRIPTION OF EXAMPLES

5 The following examples are set forth as representative of the present invention. These examples are not to be construed as limiting the scope of the invention as these and other equivalent embodiments will be apparent in view of the present disclosure and
10 accompanying claims.

EXAMPLE 1

 Poly(DL-lactide) (DL-PLA) with an inherent viscosity of 0.26 dL/g and a theoretical molecular
15 weight of approximately 10,000 daltons was prepared by the ring-opening polymerization of DL-lactide using lauryl alcohol as the initiator and stannous chloride as the catalyst. The polymer was dissolved in N-methyl-2-pyrrolidone to give a 74% by weight solution.
20 Sanguinarine hydrochloride as an orange powder was added to the polymer solution to give a 5% by weight dispersion of the drug in the polymer solution. The dispersion when added to water or saline solution formed a deep orange-colored solid precipitate which released
25 the active drug over a period of two weeks.

EXAMPLE 2

 Ethoxydihydrosanguinarine, the ethoxy ester of sanguinarine, was added to the same DL-PLA solution as
30 described in Example 1 to give a 5% by weight solution of the drug. The light brown solution when injected into water or a saline solution gave a slightly orange-colored solid precipitate which released the drug as sanguinarine over a period of two weeks.

EXAMPLE 3

The two formulations described in Example 1 and 2 were placed in 1-mL disposable syringes fitted with 21 gauge, 1.5-inch needles. Each formulation was then injected into the gingival tissue of healthy beagle dogs with artificially-created periodontal pockets. The needle was placed so that the formulation penetrated through the tissue into the periodontal pocket. As the formulation was forced from the syringe, it filled up the pocket with a rapidly solidifying mass. The needle was then withdrawn from the injection site while maintaining a flow of liquid. In this manner, both the periodontal pocket and the injection site in the gingival tissue were filled with the solid implant. After several days, the material in the periodontal pocket had been completely dislodged. However, the material in the tissue injection site was still visible. There were no signs of irritation or inflammation at the injection sites.

EXAMPLE 4

Tetracycline hydrochloride was added to the same DL-PLA solution as described in Example 1 to give a 5% by weight dispersion of drug in the solution. After standing overnight, the drug had dissolved completely into the polymer solution to give a light yellow solution. When injected into an aqueous or saline solution, the polymer coagulated to form a solid which slowly released tetracycline over a time of several weeks.

EXAMPLE 5

Poly(DL-lactide-co-glycolide) was prepared by the ring-opening polymerization of a mixture of DL-lactide and glycolide using lauryl alcohol as the initiator and stannous chloride as the catalyst. The proportions of the two monomers were adjusted so that

the final copolymer (DL-PLG) had a 50:50 ratio of the two monomers as determined by nuclear magnetic resonance spectrophotometry. The initiator was also adjusted to give a copolymer with a theoretical molecular weight of 1500 daltons. The copolymer was dissolved in N-methyl-2-pyrrolidone to give a 70% by weight polymer solution. Tetracycline as the free base was added to the polymer solution to give a 2.4% by weight solution of the drug in the polymer solution. The light yellow solution when added to water or saline formed a solid matrix as the polymer coagulated. The drug was released from the polymeric matrix over a period of two weeks.

EXAMPLE 6

Tetracycline hydrochloride was added to the same DL-PLG solution as described in Example 5 to give a 2% by weight dispersion. After standing overnight, the drug dissolved completely in the polymer solution. The solid that formed when the solution was added to water or saline released the drug at a controlled rate for a time of two weeks.

EXAMPLE 7

DLA-PLA with an inherent viscosity of 0.26 dL/g and a theoretical molecular weight of approximately 10,000 daltons was dissolved in methylene chloride to give a clear viscous solution. To this polymer solution was added ethoxydihydrosanguinarine which dissolved to give a light brown solution with 5% by weight of drug. The solution of polymer and drug was poured into a shallow dish and the methylene chloride evaporated to form a homogenous film. The dry film was then ground to give small particles of polymer/drug which could be suspended in an aqueous injection vehicle and injected directly into tissue using a standard syringe and needle.

EXAMPLE 8

Sanguinarine chloride was added to the same DL-PLA solution as described in Example 7 to give a 5% by weight dispersion. The dispersion was poured into a shallow dish and the methylene chloride evaporated to form a film with the particles of drug dispersed uniformly within the polymer matrix. The film was then ground to give small particles of polymer/drug which could be suspended in an aqueous injection vehicle and injected directly into tissue using a standard syringe and needle.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for controlled delivery of a chemotherapeutic agent to a localized site in infected gingival tissue of the mouth for of a patient having periodontal disease, comprising a polymeric delivery system formed from the chemotherapeutic agent in mixture with a polymer.
2. A pharmaceutical composition in accordance with claim 1 in which said delivery is accomplished by insertion with a syringe apparatus.
3. A pharmaceutical composition in accordance with claim 1 in which said delivery is accomplished with a trochar or a surgical incision.
4. A pharmaceutical composition in accordance with claim 1 in which said chemotherapeutic agent is selected from an antimicrobial, antibiotic, anti-inflammatory, anti-infective, peptide, protein, growth factor, antigen, biological response modifier, or vaccine.
5. A pharmaceutical composition in accordance with claim 1 in which said polymer is biodegradable.
6. A pharmaceutical composition in accordance with claim 2 in which the delivery system is selected from microspheres, microcapsules, nanoparticles, liposomes, and other small particles.
7. A polymeric composition in accordance with claim 2 in which the delivery system comprises a polymer solution containing a drug dissolved or dispersed in said solution and which solidifies to form a solid implant after injection into said tissue.

8. A polymeric composition in accordance with claim 2 in which the delivery system comprises a drug dissolved or dispersed in a liquid prepolymer that polymerizes or crosslinks to form a solid implant after injection into said tissue.

9. A polymeric composition in accordance with claim 3 in which said polymeric delivery system is in the form of a fiber, film, rod, cylinder, or pellet.

10. A polymeric composition in accordance with claim 4 in which the drug is selected from tetracycline, chlorhexidine, metronidazole, minocycline, clindamycin, sanguinarine, sanguinarine acetate, ethoxydihydrosanguinarine, sanguirubine, sanguilutine, chelirubine, chelerythrine, chelilutine, acetylsalicyclic acid, acetaminophen, ibuprofen, flurbiprofen, ketanserin, bone morphogenetic protein, fibronectin, fibrololast growth factor, platelet derived growth factor, transforming growth factor, and endothelial cell growth factor.

11. A polymeric composition in accordance with claim 5 in which said biodegradable polymer is selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), polyvinylpyrrolidone, polyethylene glycol, hydroxycellulose, methylcellulose, gelatin, collagen, and copolymers, terpolymers, or combinations or mixtures of the above materials.

12. A pharmaceutical composition in accordance with claim 1, wherein said agent is selected from the group consisting of sanguinarine hydrochloride, ethoxydihydrosanguinarine, sanguinarine acetate, chlorhexidine diacetate, chlorhexidine gluconate, tetracycline, and tetracycline hydrochloride; and wherein said polymer is selected from the group consisting of poly(DL-lactide) and poly(DL-lactide-co-glycolide).
13. A pharmaceutical composition in accordance with claim 1, wherein said agent is present in said polymer at a concentration in the range of about 1 to 80% by weight.
14. A pharmaceutical composition in accordance with claim 1, wherein said agent is present in said polymer at a concentration in the range of about 10 to 40% by weight.
15. A pharmaceutical composition in accordance with claim 12, wherein said agent and said polymer are present in a liquid carrier.
16. A pharmaceutical composition in accordance with claim 15, wherein said liquid carrier comprises a solvent for said agent and said polymer.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 90/03762

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: A 61 K 6/00, 9/51, 9/22, 9/20

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System |

Classification Symbols

IPC⁵

A 61 K

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched ⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	WO, A, 9003768 (SOUTHERN RESEARCH INSTITUTE) 19 April 1990 see claims; page 3, lines 4-13; page 4, lines 20-28; page 5, lines 1-25; page 8, lines 15-37; page 12, line 16 - page 13, line 20; page 14, lines 19-33 ---	1-16
X	EP, A, 0330180 (BIOMATERIALS UNIVERSE) 30 August 1989 see claims; page 3, line 38 - page 4, line 4; page 6, line 1 ---	1-2, 4-6, 10-16
X	Patent Abstracts of Japan, volume 10, no. 31 (C-327), 6 February 1986, & JP, A, 60184027 (RAION K.K.), 19 September 1985 see abstract ---	1-4
Y	---	5-16
	./.	

¹⁰ Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

4th March 1991

Date of Mailing of this International Search Report

08.04.91

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

miss T. MORTENSEN

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	EP, A, 0375127 (GENENTECH) 27 June 1990 see claims; column 5, lines 17-24; column 10, line 27 - column 12, line 2 ---	5-16
A	US, A, 4774091 (Y. YAMAHIRA) 27 September 1988 see claims; column 1, line 37 - column 2, line 19; column 4, lines 21-32 ---	3,11
A	EP, A, 0244118 (PHARMETRIX) 4 November 1987 ---	
A	EP, A, 0297535 (VIPONT) 4 January 1989 -----	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9003762
SA 38720

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 18/03/91
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 9003768	19-04-90	US-A- 4938763 AU-A- 4501789	03-07-90 01-05-90
EP-A- 0330180	30-08-89	JP-A- 1216918	30-08-89
EP-A- 0375127	27-06-90	AU-A- 4524889 WO-A- 9004974	28-05-90 17-05-90
US-A- 4774091	27-09-88	JP-A- 61236729 JP-A- 60084213 JP-A- 60097918 JP-A- 60126217 JP-A- 60227772 JP-A- 60129057 AU-B- 587443 EP-A- 0139286 EP-A- 0138216 EP-A- 0140255 US-A- 4855134	22-10-86 13-05-85 31-05-85 05-07-85 13-11-85 10-07-85 17-08-89 02-05-85 24-04-85 08-05-85 08-08-89
EP-A- 0244118	04-11-87	US-A- 4780320 AU-A- 7211287 JP-A- 63027422 US-A- 4919939	25-10-88 05-11-87 05-02-88 24-04-90
EP-A- 0297535	04-01-89	AU-A- 1849988 JP-A- 1085916	05-01-89 30-03-89